A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

Clinical trial NCT05465590 · WITHDRAWN

Trial details

NCT number: NCT05465590
Sponsor: Mainline Biosciences, Inc.
Status: WITHDRAWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Breast Cancer Non Small Cell Lung Cancer Ovary Cancer Pancreatic Neoplasms

Start date: 2022-12-01
Primary completion: 2024-11-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.